TABLE 1.

Systemic treatment of choice after disease progression

Recurrence	Cht (number of patients)
First	Bevacizumab + Irinotecan 12 (63.2%)
	BCNU 2
	TMZ 4
	PCV 1
Second	Bevacizumab + Irinotecan 5 (26.3%)
	BCNU 1
	PCV 1
Third	Bevacizumab + Irinotecan 2 (10.5%)

BCNU = Carmustine (BCNU), 80 mg/m2 BCNU on days 1 on 3; Cht = chemotherapy; PCV = lomustine (CCNU), 110 mg/m2, on day 1; procarbazine, 60 mg/m2 on days 8 to 21; and vincristine, 1.5 mg/m2 (maximum dose, 2 mg), on days 8 and 29; TMZ = temozolomide, 150–200 mg/m2/day on days 1 to 5 of each subsequent 28-day cycle